Denise P. Carter - 03 Sep 2024 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Signature
/s/ Denise Carter
Issuer symbol
QNRX
Transactions as of
03 Sep 2024
Net transactions value
+$28,737
Form type
4
Filing time
05 Sep 2024, 12:06:41 UTC
Previous filing
30 Oct 2023
Next filing
10 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNRX Ordinary Shares Purchase $1,139 +1,822 +19% $0.6253 11,179 03 Sep 2024 Direct F1, F2
transaction QNRX Ordinary Shares Purchase $2,686 +4,100 +37% $0.6551 15,279 03 Sep 2024 Direct F1
transaction QNRX Ordinary Shares Purchase $6,602 +8,825 +58% $0.7481 24,104 04 Sep 2024 Direct F1
transaction QNRX Ordinary Shares Purchase $18,310 +22,988 +95% $0.7965 47,092 04 Sep 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer.
F2 Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023.